- #Nytimes store plus#
- #Nytimes store professional#
Your doctor may prescribe other medicines for you to take along with EDARBI or EDARBYCLOR to treat your high blood pressure.
ĮDARBI and EDARBYCLOR are prescription medicines used to treat high blood pressure (hypertension). Medical Information at 1-86 or to the FDA at or call 1-80. You are encouraged to report side effects of prescription drugs to Azurity Pharmaceuticals, Inc.
#Nytimes store professional#
Please talk to your healthcare professional and see complete Prescribing Information for EDARBI and EDARBYCLOR.
In a clinical study, the side effects seen with EDARBYCLOR included dizziness (8.9%) and tiredness (2.0%). In clinical studies, the most common side effect seen with EDARBI was diarrhea (2.0%). If you already have gout, tell your doctor about worsening of your gout symptoms. People who have increased levels of uric acid in the blood may develop gout. If you have fluid and body salt (electrolyte) problems, tell your doctor if you experience any of the following symptoms: dry mouth, confusion, thirst, lack of energy (lethargic), weakness, drowsiness, passing very little urine or passing large amounts of urine, seizures, muscle pain/cramps, restlessness, muscle tiredness (fatigue), fast or abnormal heartbeat, nausea and vomiting, or constipation. If you pass out (faint), have someone call your doctor or get medical help. If you feel faint or dizzy, lie down and call your doctor right away. Vomiting and diarrhea, a low salt diet, sweating a lot, or not drinking enough fluid can also lead to low blood pressure. EDARBI and EDARBYCLOR may cause serious side effects, including low blood pressure (hypotension) which may cause you to feel faint or dizzy. Especially tell your doctor if you take other medicines to treat your high blood pressure or heart problem water pills (diuretics) lithium or digoxin. Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. During treatment with EDARBI or EDARBYCLOR, certain people who have severe heart failure, narrowing of the artery to the kidney, or who lose too much body fluid such as with nausea, vomiting, bleeding, or trauma, may develop sudden kidney failure and in rare instances, death. If you have kidney problems, you may need blood tests, and your doctor may need to lower your dose or may need to stop treatment with EDARBYCLOR. Kidney problems may become worse in people that already have kidney disease. Tell your doctor about all your medical conditions, including if you have heart problems or stroke, have gout, or have liver or kidney problems. 
Do not take aliskiren-containing products with EDARBI or EDARBYCLOR if you have diabetes. Do not take EDARBYCLOR if you make less urine because of kidney problems (anuria). Breastfeeding while taking EDARBI or EDARBYCLOR is not recommended. Discuss with your doctor other ways to lower your blood pressure. Before taking EDARBI or EDARBYCLOR, tell your doctor if you are breastfeeding or plan to breastfeed. If you plan to become pregnant, talk to your doctor about other treatments to lower blood pressure. If you become pregnant while taking EDARBI or EDARBYCLOR, tell your doctor right away. WARNING: EDARBI ® (azilsartan medoxomil) and EDARBYCLOR ® (azilsartan medoxomil/chlorthalidone) can cause harm or death to your unborn baby. Atlanta, GA: Azurity/Arbor Pharmaceuticals, LLC. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Low blood pressure - when blood pressure is too low. 
African Americans, hypertension and the renin angiotensin system. Williams SF, Nicholas SB, Vaziri ND, Norris KC.
Comparison of effectiveness of azilsartan medoxomil and olmesartan in Blacks versus whites with systemic hypertension. Ferdinand KC, Bakris GL, Cushman WC, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Heart disease and stroke statistics-2020 update: a report from the American Heart Association.
#Nytimes store plus#
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.
0 kommentar(er)
